7921 Southpark Plaza
Suite 210
Littleton, CO 80120
United States
844 672 4357
https://www.vivos.com
Settore/i: Healthcare
Settore: Medical Devices
Impiegati a tempo pieno: 114
Nome | Titolo | Retribuzione | Esercitate | Anno di nascita |
---|---|---|---|---|
Mr. R. Kirk Huntsman | Co-Founder, Chairman of the Board & CEO | 482,16k | N/D | 1958 |
Mr. Bradford K. Amman | CFO, Treasurer & Secretary | 335,53k | N/D | 1962 |
Mr. Todd Huntsman | Co-Founder & Senior VP of Product and Technology | N/D | N/D | N/D |
Ms. RaeAnn Byrnes | Co-Founder and Senior VP of Events & Clinical Advisory Services | N/D | N/D | N/D |
Ms. Susan McCullough | Co-Founder & Executive VP of Operations | N/D | N/D | N/D |
Ms. Julie Gannon | Senior VP of Strategic Sales & Marketing and Investor Relations Officer | N/D | N/D | N/D |
Mr. Nicholas M. DeGennaro | Senior Vice President of Medical Integration Division | N/D | N/D | N/D |
Ms. Ruth Hembree | Senior Vice President of Practice Services | N/D | N/D | N/D |
Ms. Stephanie Huebner | Senior Vice President of Dental Service Integration | N/D | N/D | N/D |
Mr. John Ballard | Senior Vice President of Technology | N/D | N/D | N/D |
Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada. Vivos Therapeutics, Inc. was founded in 2016 and is based in Littleton, Colorado.
L'ISS Governance QualityScore di Vivos Therapeutics, Inc. al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.